Spots Global Cancer Trial Database for daratumumab sc
Every month we try and update this database with for daratumumab sc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab | NCT04270175 | Amyloid AL Amyloidosis Refractory AL A... | Daratumumab SC Pomalidomide Dexamethasone | 18 Years - | Weill Medical College of Cornell University | |
| A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | NCT02195479 | Multiple Myelom... | Velcade Melphalan Prednisone Daratumumab IV Dexamethasone Daratumumab SC | 18 Years - | Janssen Research & Development, LLC | |
| Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | NCT02252172 | Multiple Myelom... | Daratumumab IV Lenalidomide Dexamethasone Daratumumab SC | 18 Years - | Janssen Research & Development, LLC | |
| INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | NCT03837509 | Relapsed or Ref... | INCB001158 Daratumumab SC | 18 Years - | Incyte Corporation | |
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma | NCT05907759 | Lymphoma, Prima... | Daratumumab SC | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | NCT02195479 | Multiple Myelom... | Velcade Melphalan Prednisone Daratumumab IV Dexamethasone Daratumumab SC | 18 Years - | Janssen Research & Development, LLC | |
| Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) | NCT06100237 | Multiple Myelom... | Teclistamab Talquetamab Daratumumab SC | 18 Years - | University of Miami | |
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma | NCT05907759 | Lymphoma, Prima... | Daratumumab SC | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT05050097 | Multiple Myelom... | Talquetamab Carfilzomib Daratumumab SC Lenalidomide Pomalidomide | 18 Years - | Janssen Research & Development, LLC | |
| A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab | NCT04302324 | Multiple Myelom... Refractory Mult... Relapse Multipl... | Daratumumab SC Clarithromycin Pomalidomide Dexamethasone | 18 Years - 75 Years | Weill Medical College of Cornell University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
